Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle.
D000818:Animals; D000903:Antibiotics, Antineoplastic; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002147:Calmodulin / Q000037:antagonists & inhibitors; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004347:Drug Interactions; D004351:Drug Resistance; D007941:Leukemia P388 / Q000188:drug therapy; D009279:Naphthacenes / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use; D014748:Vinca Alkaloids / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D002121:Calcium Channel Blockers; D002147:Calmodulin; D009279:Naphthacenes; D014748:Vinca Alkaloids; C001939:N-acetyldaunomycin; D014750:Vincristine; D014700:Verapamil; D003630:Daunorubicin